Intrexon Acquires Laboratory Operations from Codexis and Expands Presence to Europe

 Intrexon Acquires Laboratory Operations from Codexis and Expands Presence to

  PR Newswire

  SAN CARLOS, California, March 17, 2014

-- Company Increases Bioproduction Capabilities and Capacity

SAN CARLOS, California, March 17, 2014 /PRNewswire/ -- Intrexon Corporation
(NYSE: XON), a leader in synthetic biology, today announced that it has
acquired state-of-the-art laboratory operations in Budapest, Hungary from
Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex
chemistry industries.


The acquisition will expand Intrexon's strain and protein development
capabilities, as well as strengthen fermentation process optimization and
scale-up. Through the agreement, Intrexon's Industrial Products Division (IPD)
will absorb the Budapest laboratory staff of experienced scientific
professionals. Integration of the Budapest team and their expertise with
Intrexon's suite of synthetic biology technologies and capabilities will allow
Intrexon to better serve current collaborators and to attract new
opportunities for active pharmaceutical ingredients (API) and industrial and
consumer product collaborations.

Intrexon's IPD is positioned to develop biologically based solutions across
sectors – Health, Food, Energy, Environment, and Consumer – including
bioproduction of APIs, for example novel anti-infectives, as well as
engineering microbial biocatalysts for chemical and fuel production.

"The expansion affords Intrexon greater flexibility in existing collaborations
including Amneal , Johnson & Johnson , and Oragenics and positions the Company
to meet demand from international collaborators," said Robert F. Walsh,
President of Intrexon's Industrial Products Division. "We are pleased to
integrate the Budapest team into Intrexon and look forward to their immediate

"The state-of-the-art industrial development facility and team we have
acquired not only expands our current IPD operations, but its location in
Budapest will enable us to continue growing our interests abroad and
strengthen our ability to service the European and Asian markets," added Peter
Seufer-Wasserthal, Ph.D., Vice President of Business Development for Europe
and Asia.

About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in
synthetic biology focused on collaborating with companies in Health, Food,
Energy, Environment, and Consumer markets to create biologically-based
products that improve the quality of life and the health of the planet.
Through the company's proprietary UltraVector® platform, Intrexon provides its
partners with industrial-scale design and development of complex biological
systems. The UltraVector® platform delivers unprecedented control over the
quality, function, and performance of living cells. We call our synthetic
biology approach and integrated technologies Better DNA®, and we invite you to
discover more at .

Trademarks Intrexon, UltraVector, RheoSwitch Therapeutic System, RTS, AttSite,
mAbLogix, LEAP, and Better DNA are trademarks of Intrexon and/or its
affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement Some of the statements made in this press release are
forward-looking statements. These forward-looking statements are based upon
our current expectations and projections about future events and generally
relate to our plans, objectives and expectations for the development of our
business. Although management believes that the plans and objectives reflected
in or suggested by these forward-looking statements are reasonable, all
forward-looking statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release.

For more information contact:

Intrexon Corporation Marie L. Rossi, Ph.D. Manager, Technical Communications
Tel: +1-301-556-9944 Email:

Press spacebar to pause and continue. Press esc to stop.